Robert Friedman, MD
Neurology · Palm Beach Gardens, FLNPI 1659465375
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 181 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 47.5% of the total.
Across 181 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Pfizer$423
- Teva Pharmaceuticals USA, Inc.$352
- Lundbeck LLC$282
- Amgen$168
- Bausch Health US, LLC$143
- plus $358 from 11 others
What the payments were for
- Food & beverage$3,282100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 100 | $1,558 |
| Pfizer | 20 | $423 |
| Teva Pharmaceuticals USA, Inc. | 16 | $352 |
| Lundbeck LLC | 11 | $282 |
| Amgen | 7 | $168 |
| Bausch Health US, LLC | 8 | $143 |
| Lilly USA, LLC | 3 | $56 |
| Upsher-smith Laboratories LLC | 3 | $55 |
| Eisai Inc. | 3 | $50 |
| Neuronetics, Inc. | 2 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 1 | $26 |
| Assertio Therapeutics, Inc. | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Zyla Life Sciences, Inc. | 1 | $21 |
| Sonex Health, Inc. | 1 | $18 |
| Impel Pharmaceuticals Inc. | 1 | $13 |
How this compares
$3,282 in reported general payments places this provider in the 55th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 13 | $9,839 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 19 | $1,190 |
| Duloxetine Hcl | 14 | $272 |
| Donepezil Hcl | 14 | $154 |
| Tramadol Hcl | 12 | $11 |
Paid to pharmacies, not to this prescriber.
Other neurology in Palm Beach Gardens
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
- Lance KimOcala$1M
- Tuan VuTampa$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.